We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Agronomics Limited | LSE:ANIC | London | Ordinary Share | IM00B6QH1J21 | ORD 0.0001P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.10 | -1.67% | 5.90 | 5.90 | 6.10 | 6.00 | 6.00 | 6.00 | 1,407,346 | 16:35:17 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Investors, Nec | 30.88M | 22.37M | 0.0222 | 2.70 | 60.56M |
From Jul 2019 to Jul 2024
TIDMPEBI
RNS Number : 8179U
Port Erin Biopharma Investments Ltd
21 October 2014
For immediate release
21 October 2014
Port Erin Biopharma Investments Limited
(the "Company")
Net Asset Value calculation to 30 September 2014
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 30 September 2014 was 14.42 pence per share, including un-invested cash of GBP490,797. The accrual of GBP379,053 for the management fee has now been settled. The portfolio is valued under IFRS at bid price.
Total Assets stand at GBP4.9 million and Investments stand at GBP4.4 million. This quarter's NAV represents a decrease of 1.97% from the previous valuation of 14.71 pence per share, which included un-invested cash of GBP526,503. On this basis, no additional management fee is due to Shellbay Investments Limited.
Our holding in the Magna Biopharma Income Fund continues to perform well, the value having risen by 12% to GBP2.6 million in the nine months since inception.
The Directors' intend to make a further announcement about the distribution of Magna Biopharma Income Fund shares at the end of the month which marks the conclusion of the lock-in period."
Hot Features
Premium
Unaudited
to 30 September 2014
GBP
Fixed Assets
Investments 4,408,633
Current Assets
Debtors: amounts owing 24,477
Un-invested cash 490,797
Current Liabilities
Creditors: amounts due (39,027)
4,884,880
Capital and Reserves
Share Capital 34
Share Premium 2,759,551
Current year's earnings (96,546)
Retained earnings 2,221,841
4,884,880
Shares in Issue 33,864,836
Asset Value per share 14.42 pence
--- ENDS ---
Portfolio Details
Investments as at 30 September Value % of Total Portfolio 2014 Magna Biopharma Income Fund GBP2,613,899 59.29% Plethora Solutions Holdings GBP600,625 13.62% Summit Corporation GBP586,499 13.30% Other quoted holdings GBP209,110 4.74% Other unquoted holdings GBP398,500 9.04% Total GBP4,408,633 100.00% -------------------------------- -------------- ---------------------
For further information, please contact:
Port Erin Biopharma Beaumont Cornish Limited Peterhouse Capital Investments Limited Limited The Company Nomad Broker Denham Eke Roland Cornish Guy Miller +44 162 463 9396 +44 207 628 3396 +44 207 469 0930
This information is provided by RNS
The company news service from the London Stock Exchange
END
NAVDBLFLZBFXFBX
1 Year Agronomics Chart |
1 Month Agronomics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
